

Scandiatransplant



Annual Meeting 2024

November 19th,
Kastrup, Copenhagen 10:30-15.30

Minutes of Meeting:

1. Welcome Helle Thiesson

2. Writer of minutes Ida Maria Schmidt

3. Minutes from the last meeting were approved.

4. Presentation of participants

- A list of meeting participants is found at the end of these minutes
- Mailing list updated: country representatives are responsible for keeping the list updated.

5. All key persons were reelected.

- Helle Thiesson (DK)
- Inga Vainumäe (EST)
- Timo Jahnukainen (FIN)
- Vidar Örn Edverdsson (ISL)
- Ann Christin Gjerstad (NOR)
- Lars Wennberg (SWE)
- Søren Schwartz Sørensen (NKG)

6. Annual report (Søren Schwartz Sørensen, Denmark):

The report will soon be available on the Scandiatransplant website: <https://www.scandiatransplant.org/members/nkg/nprtsg>

The age cutoff for pediatric patients has been updated from 16 to 18 years.

7. NPRTSG History (1994-2024) (Søren Schwartz Sørensen, Denmark):

NPRTSG was founded in 1994 by Ulla Berg and Gunnar Tydén. The first meeting was held on April 15, 1994. The objective was: to establish a standalone database, annual reporting, and meetings. Participants included all healthcare professionals in the field of pediatric renal transplantation.

2010: Database merged with Scandiatransplant database (YASWA).

2016: NPRTSG became a subgroup under the Nordic Kidney Group within Scandiatransplant. Publications: Numerous publications have been produced.

8. Status on ERN TransplantChild and PETER Register (Lars Wennberg online):

A subgroup within the ERN Transplant Child initiative. Working groups are active at the EU level. In Stockholm, they focus on WP7: Educational material and guidelines for pets, vaccinations, CMV, FSG recurrence, and minimizing immunosuppression.

PETER: Includes all transplants, including bone marrow. Goal: to include 40% of all transplants using PedsQL.

Discussion about the lack of cooperation among different EU registries under ERN.

Consent is mandatory but varies between Nordic countries.

9. Risk and prognosis of post-transplant lymphoproliferative disease in Epstein-Barr virus - seronegative kidney transplant recipients (pediatric and adult) - An observational cohort study from Norway and Western Denmark (Lene Ugilt P. Ludvigsen, Denmark):

Three different classifications were reviewed. PTLD incidence:

14% in high-risk children.

7% in high-risk adults.

Rituximab appears to protect against PTLD, while basiliximab seems to increase the risk.

10. PTLD status and future project in NPRTSG (Ann Christin Gjerstad, Norway). Study proposals and ideas were discussed.

11, 13. Association of HLA B and T cell molecular mismatches with HLA antibodies, rejection and graft survival in pediatric kidney transplantation. The impact of reduced immunosuppression on alloimmunity: A retrospective study of pediatric kidney transplant recipients. (AM Gramkow, Denmark)

Annual HLA testing.

Hospitalizations, infections, and survival versus DS antibodies.

Protocol: Tacrolimus + MMF + Basiliximab.

Reasons for reduction: Leukopenia, viral infections, abdominal issues.

Indications of over-suppression: Infections, hospitalizations, and infection rates. Younger patients experience more hospitalizations and infections.

Rejection rates:

1 year: 4%.

5 years: 10%.

HLA immunization (Luminex):

De novo DSA: 11% impact on graft survival.

HLA-sensitized: 60% (no significant impact on organ survival). Compared to other studies, this rate is lower.

12. Use of Imlifidase for Desensitization (Lars Wennberg, Sweden, online):

Presentation of an ongoing study.

Patients can be included via LW.

Study involves living and deceased donors.

14. Review of Immunosuppressive Regimens (Helle Thiesson, Denmark):

MMF AUC target: 30-50.

Discussion on basiliximab: its effect is inconclusive.

Prednisolone: Can it be phased out? Concerns about metabolic effects, growth, infections, and cancer. The possibility of stopping steroids was discussed. ERN Transplant Child guideline on steroid tapering was mentioned.

Discussion on protocols:

Finland protocol biopsies at 3 months, 18 months, and 3 years.

DSA measured once a year.

MMF-AUC: Norwegian calculator.

Next meeting: Review ERN Transplant Child's steroid protocol.

15. Research Proposals:

A) Randomized controlled study of Rituximab pre-transplantation in EBV seronegative patients.

B) Interaction between chronic kidney disease and psychiatric disorders:

Incidence up to 53%.

Correlation between nonadherence and psychiatric disorders.

Proposal: Study prevalence in Nordic countries, diagnostic methods, impact of psychiatric comorbidity on transplantation outcomes, long-term mental health outcomes, and management strategies.

16. Any other business?

Patients with Neurological Delayed Psychomotor Development:

Discussion on when to offer RRT (dialysis and transplant).

No conclusion was reached, but experiences were shared.

17. Next Meetings:

2026: Helsinki

2025: Sweden (Skåne), November 18th, in Kastrup

2024: Copenhagen

2023: Stockholm

2022: (COVID)

2021: Helsinki

2020: Oslo

Meeting participants:

Anne Ørskov Boserup
Ylinen Elisa
Jahnukainen Timo
Savonius Okko
Elisa Ylinen
Zivile Bekassy
Maria Herthelius
Tomas Lorant
Marie Tranäng
Susanne Westphal
Mia Dursun
Åse Noren
Ann Christin Gjerstad
Inga Vainumäe
Søren Rittig
Hanne Nørgaard
Line Thousig Sehested
Ida Maria Schmidt
Søren Schwatz Sørensen
Ann Maria Gramkow
Lene Ugilt Pagter Ludvigsen
Line aas Mortensen
Helle C Thiesson
Mette Neland
Marita Bladh (online)
Lars Wennberg (online)